



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

5 October 2020

Issue of unlisted performance options under Equity Incentive Plan

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer advises that it has today lodged an Appendix 3G for the issue of 10,150,000 Unlisted Performance Options.

Following the approval of the Equity Incentive Plan at the company's Annual General Meeting held on 29 July 2020, the Board of Directors has approved the issuance of Unlisted Performance Options to employees of Imagion Biosystems, excluding the CEO, who are eligible to participate in the company's incentive scheme.

The options have an exercise price of \$0.0909 per share vesting over three years with expiry dates between 30 September 2025 to 31 August 2028.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828